Omission of drug dose information [3]

Archives of Internal Medicine

Volumn 166, Issue 3, 2006, Pages 368-

  Hollenberg, Norman K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFORMATION; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LETTER; LOW DRUG DOSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHLORTHALIDONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; LISINOPRIL; RANDOMIZED CONTROLLED TRIALS;

EID: 32644445444     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.166.3.368-b     Document Type: Letter

References (1)

1. Rahman M, Pressel S, Davis BR, et al; ALLHAT Collaborative Research Group. Renal outcomes in high-risk hypertensive patients treated with an angiotensinconverting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936-946.